可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Kim MS,Klein AJ,Carroll JD.Transcatheter closure of intracardiac defects in adults[J].J Interv Cardiol,2007,20(6):524-545.
[2]Cohnheim J.Thrombose und nbolie: Vorlesungen über allgemeine pathologie, Vol 1[M].Berlin:Hirschwald,1877,1:134.
[3]Sacco RL,Ellenberg JH,Mohr JP,et al.Infarcts of undetermined cause:the NNCDS Stroke Date Bank[J].Ann Neurol,1989,25(4):382-390.
[4]Lechat P,Mas JL,Lascault G,et al.Prevalence of patent foramen ovale in patients with stroke[J].N Engl J Med,1988,318(18):1148-1152.
[5]Webster MW,Chancellor AM,Smith HJ,et al.Patent foramen ovale in young stroke patients[J].Lancet,1988,2(8601):11-12.
[6]Di Tullio M,Sacco RL,Gopal A,et al.Patent foramen ovale as a risk factor for cryptogenic stroke[J].Ann Intern Med,1992,117(6):461-465.
[7]Handke M,Harloff A, Olschewski M.Patent foramen ovale and cryptogenic stroke in older patients[J].N Engl J Med,2007,357(22):2262-2268.
[8]Overell JR, Bone I,Lees KR,et al.Interatrial septal abnormalities and stroke:a metaanalysis of casecontrol studies[J].Neurolog,2000,55(8):1172-1179.
[9]Cramer SC,Rordorf G,Maki JH,et al.Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke(PELVIS)study[J].Stroke,2004,35(1):46-50.
[10]Meissner I,Khandheria BK,Heit JA,et al.Patent foramen ovale:innocent or guilty?Evidence from a prospective populationbased study[J].J Am Coll Cardiol,2006,47(2):440-445.
[11]Mohr J,Thompson JLP,Lazar RM,et al.for the WarfarinAspirin Recurrent Stroke Study Group.A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke[J].N Engl J Med,2001,345(20):1444-1451.
[12]Homma S,Sacco RL,Tullio MR,et al.for the PFO in Cryptogenic Stroke Study(PICSS)Investigators. Effect of medical treatment in stroke patients with patent foramen ovale:patent foramen ovale in cryptogenic stroke study[J].Circulation,2002,105(22):2625-2631.
[13]Bridges ND,Hellenbrand W,Latson L, et al.Transcatheter closure of patent foramen ovale after presumed paradoxical embolism[J].Circulation,1992,86(6):1902-1908.
[14]Windecker S,Wahl A,Nedeltchev K,et al.Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke[J].J Am Coll Cardiol,2004,44(4):750-758.
[15]Khairy P,O’Donmell CP,Landzberg MJ.Transcatheter cloure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli:asystematic review[J].Am Intern Med,2003,139(9):753-760.
[16]Furlan AJ,Reisman M,Massaro J,et al.Study design of the CLOSURE I trial:a prospective,multicenter,randomized,controlled trial to evaluate the safety and efficacy of the StarFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale[J].Stroke,2010, 41(12):2872-2883.
[17]Kitsios GD,Dahabreh IJ,Abu Dabrh AM,et al.Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence[J].Stroke,2012,43(2):422-431.
[18]Ford MA,Reeder GS,Lennon RJ,et al.Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack:the Mayo Clinic experience[J].JACC Cardiovasc Interv,2009,2(5):404-411.
[19]Fischer D,Haentjes J,Klein G,et al.Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and followup results after implantation of the Amplatzer occluder device[J].J Interv Cardiol,2011,24(1):85-91.
[20]Khattab AA,Windecker S,Juni P,et al.Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO occluder with medical treatment in patients with cryptogenic embolism(PCtrial):rationale and design[J].Trials,2011,12:56.